MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 207 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $444,692 | -31.1% | 3,045 | +8.9% | 0.21% | -30.4% |
| Q2 2023 | $645,876 | -4.6% | 2,796 | 0.0% | 0.30% | -46.4% |
| Q1 2023 | $677,359 | +9.4% | 2,796 | -70.7% | 0.55% | +55.9% |
| Q3 2022 | $619,000 | +79.9% | 9,527 | +98.5% | 0.35% | +70.2% |
| Q2 2022 | $344,000 | -22.5% | 4,800 | +6.1% | 0.21% | -26.2% |
| Q1 2022 | $444,000 | – | 4,525 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |